Author: Lindsey Bailin

Pharmaceutical giant Johnson & Johnson has set aside $3.9 billion for talc-related litigation, according to a regulatory filing this week with the Securities and Exchange Commission in Washington D.C. The company said it’s now facing more than 25,000 lawsuits related to various talc products that have allegedly caused cancers, primarily from asbestos fiber contamination. The $3.9 billion is almost […]

The post Johnson & Johnson Preparing $3.9 Billion for Talc Settlements appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Thoracic surgeon Dr. Bryan Burt at the Baylor College of Medicine wants to better identify which patients with pleural mesothelioma cancer will benefit (and which will not) from promising immunotherapy drugs such as Keytruda and Opdivo. No test currently exists to make that determination accurately, often leading to unnecessary treatments with adverse side effects and […]

The post Study: Which Mesothelioma Patients Will Immunotherapy Benefit? appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from the FDA. […]

The post FDA Fast-Tracks Mesothelioma Vaccine Development appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.